8C8T
cryo-EM structure of BG505 SOSIP.664 HIV-1 Env trimer in complex with bNAbs EPTC112 and 3BNC117
This is a non-PDB format compatible entry.
Summary for 8C8T
| Entry DOI | 10.2210/pdb8c8t/pdb |
| EMDB information | 16493 |
| Descriptor | Envelope glycoprotein gp160, 2-acetamido-2-deoxy-beta-D-glucopyranose, Gp41 Bg505 T332n Sosip.664, ... (10 entities in total) |
| Functional Keywords | hiv, post-treatment controller, broadly neutralizing antibodies, v3-site, immune system |
| Biological source | Human immunodeficiency virus 1 More |
| Total number of polymer chains | 14 |
| Total formula weight | 410177.48 |
| Authors | Baquero, E.,Molinos-Albert, L.,Mouquet, H. (deposition date: 2023-01-21, release date: 2023-07-05, Last modification date: 2024-11-06) |
| Primary citation | Molinos-Albert, L.M.,Baquero, E.,Bouvin-Pley, M.,Lorin, V.,Charre, C.,Planchais, C.,Dimitrov, J.D.,Monceaux, V.,Vos, M.,Hocqueloux, L.,Berger, J.L.,Seaman, M.S.,Braibant, M.,Avettand-Fenoel, V.,Saez-Cirion, A.,Mouquet, H. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller. Cell Host Microbe, 31:1275-, 2023 Cited by PubMed Abstract: HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may contribute to natural HIV-1 control in individuals off antiretroviral therapy (ART). Here, we describe a bNAb B cell lineage elicited in a post-treatment controller (PTC) that exhibits broad seroneutralization and show that a representative antibody from this lineage, EPTC112, targets a quaternary epitope in the glycan-V3 loop supersite of the HIV-1 envelope glycoprotein. The cryo-EM structure of EPTC112 complexed with soluble BG505 SOSIP.664 envelope trimers revealed interactions with N301- and N156-branched N-glycans and the GDIR V3 loop motif. Although the sole contemporaneous virus circulating in this PTC was resistant to EPTC112, it was potently neutralized by autologous plasma IgG antibodies. Our findings illuminate how cross-neutralizing antibodies can alter the HIV-1 infection course in PTCs and may control viremia off-ART, supporting their role in functional HIV-1 cure strategies. PubMed: 37433296DOI: 10.1016/j.chom.2023.06.006 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.2 Å) |
Structure validation
Download full validation report
